Lagos, Nigeria – 17 July 2026
MeCure Industries PLC participated in the High-Level Stakeholders' Meeting on the NMEP-World Bank-funded IMPACT Project, anchored by the National Institute for Pharmaceutical Research and Development (NIPRD). The meeting brought together government officials, development partners, regulators, and pharmaceutical industry leaders to discuss strategies for strengthening local medicine manufacturing in Nigeria.

Lagos, Nigeria – 10 July 2026
This video covers the Annual General Meeting (AGM) of MeCure Industries Plc, held on July 10, 2026. The session served as a platform for reviewing the company's financial results for the 2025 fiscal year and securing shareholder approval for key operational and financial resolutions.

Lagos, Nigeria – 01 July 2026
MeCure Industries PLC has received Halal Certification from the Halal Certification Authority for its multivitamin products, Just One and Solmate Tablets.
The certification confirms that the listed products meet the required Halal standards and further strengthens MeCure’s commitment to quality, consumer trust, and inclusive healthcare delivery. This milestone supports the company’s broader objective of making safe, affordable, and quality medicines accessible to diverse communities across Nigeria and export markets.

Lagos, Nigeria – 1st Quarter 2026
In the first quarter of 2026, MeCure Industries PLC delivered a strong financial performance, navigating a still-challenging but gradually stabilizing macroeconomic environment in Nigeria and globally. The Company recorded revenue of ₦20.15 billion, representing a 52% year-on- year growth, alongside Profit Before Tax (PBT) of ₦1.92 billion, up 136% year-on-year, and Earnings Per Share (EPS) of ₦0.34, reflecting a 143% year-on-year increase.

Lagos, Nigeria – 1st April 2026
MeCure Industries PLC, a leading pharmaceutical manufacturer in Nigeria, is pleased to announce the successful and full redemption of its ₦3 billion Senior Secured Bond (Series 1) issued under its ₦20 billion Debt Issuance Programme.
The bond, originally issued on 14th May 2021, marked the company’s debut transaction in the Nigerian capital market. The full repayment underscores MeCure’s strong financial discipline, robust cash flow management, and commitment to meeting its obligations to investors.

In a landmark stride that reinforces its commitment to innovation and accessibility, MeCure Industries PLC has unveiled an impressive portfolio of 19 newly approved pharmaceutical products in 2025, marking one of the most significant expansion phases in the company’s history.
The development signals more than just regulatory milestones — it reflects MeCure’s strategic intent to deepen therapeutic coverage across Nigeria, strengthen its presence in chronic care, and further its mission of “Enriching Lives through Innovation in Pharmaceuticals.”

NGX Ticker: MECURE
Lagos, Nigeria - 08 November 2023
MeCure Industries has satisfied the listing requirements of the Nigerian Exchange Limited and obtained all relevant regulatory approvals. We are now listed in the pharmaceutical sector of the Exchange, with the ticker “MECURE”.
Read More

NGX Ticker: MECURE
Lagos, Nigeria - 08 November 2024
MeCure Industries Plc is pleased to announce the official implementation of its Track & Trace solution, a program with cutting edge technology ensuring product safety for our customers.
Read More
